Tyrosine Kinase Signalling in Breast Cancer: ErbB Family Receptor Tyrosine Kinases

Overview

Journal Breast Cancer Res

Specialty Oncology

Date 2001 Mar 16

PMID 11250707

Citations 54

Authors

D F Stern

Affiliations

Soon will be listed here.

Abstract

ERBB family receptor tyrosine kinases are overexpressed in a significant subset of breast cancers. One of these receptors, HER2/neu, or ErbB-2, is the target for a new rational therapeutic antibody, Herceptin. Other inhibitors that target this receptor, and another family member, the epidermal growth factor (EGF) receptor, are moving into clinical trials. Both of these receptors are sometimes overexpressed in breast cancer, and still subject to regulation by hormones and other physiological regulators. Optimal use of therapeutics targeting these receptors will require consideration of the several modes of regulation of these receptors and their interactions with steroid receptors.

Citing Articles

Phosphatidylinositol 4,5-bisphosphate drives the formation of EGFR and EphA2 complexes.

Kumar Singh P, Rybak J, Schuck R, Sahoo A, Buck M, Barrera F Sci Adv. 2024; 10(49):eadl0649.

PMID: 39630914 PMC: 11616708. DOI: 10.1126/sciadv.adl0649.

Sprouty genes regulate activated fibroblasts in mammary epithelial development and breast cancer.

Li J, Ma R, Wang X, Lu Y, Chen J, Feng D Cell Death Dis. 2024; 15(4):256.

PMID: 38600092 PMC: 11006910. DOI: 10.1038/s41419-024-06637-2.

Anticancer potential of novel symmetrical and asymmetrical dihydropyridines against breast cancer EGFR inhibition: molecular design, synthesis, analysis and screening.

Faizan S, Talath S, Wali A, Hani U, Haider N, Mandal S RSC Adv. 2024; 14(16):11368-11387.

PMID: 38595721 PMC: 11002980. DOI: 10.1039/d4ra01424c.

Endosomal recycling inhibitors downregulate estrogen receptor-alpha and synergise with endocrine therapies.

Fletcher K, Alkurashi M, Lindsay A Breast Cancer Res Treat. 2024; 204(3):631-642.

PMID: 38228924 PMC: 10959794. DOI: 10.1007/s10549-023-07225-2.

A Unified Bayesian Framework for Bi-overlapping-Clustering Multi-omics Data via Sparse Matrix Factorization.

Zhou F, He K, Cai J, Davidson L, Chapkin R, Ni Y Stat Biosci. 2024; 15(3):669-691.

PMID: 38179127 PMC: 10766378. DOI: 10.1007/s12561-022-09350-w.

References

Jones F, Stern D . Expression of dominant-negative ErbB2 in the mammary gland of transgenic mice reveals a role in lobuloalveolar development and lactation. Oncogene. 1999; 18(23):3481-90. DOI: 10.1038/sj.onc.1202698. View

Pietras R, Fendly B, Chazin V, Pegram M, Howell S, Slamon D . Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells. Oncogene. 1994; 9(7):1829-38. View

Schweitzer R, Howes R, Smith R, Shilo B, Freeman M . Inhibition of Drosophila EGF receptor activation by the secreted protein Argos. Nature. 1995; 376(6542):699-702. DOI: 10.1038/376699a0. View

Dickson C, Spencer-Dene B, Dillon C, Fantl V . Tyrosine kinase signalling in breast cancer: fibroblast growth factors and their receptors. Breast Cancer Res. 2001; 2(3):191-6. PMC: 138774. DOI: 10.1186/bcr53. View

HURWITZ E, Pirak M, Bellot F, Schlessinger J, Sela M . Efficacy of antibodies to epidermal growth factor receptor against KB carcinoma in vitro and in nude mice. J Natl Cancer Inst. 1988; 80(20):1605-11. DOI: 10.1093/jnci/80.20.1605. View

Kwong K, Hung M . A novel splice variant of HER2 with increased transformation activity. Mol Carcinog. 1998; 23(2):62-8. DOI: 10.1002/(sici)1098-2744(199810)23:2<62::aid-mc2>3.0.co;2-o. View

Arteaga C, Winnier A, Poirier M, Shawver L, Hurd S, Stewart S . p185c-erbB-2 signal enhances cisplatin-induced cytotoxicity in human breast carcinoma cells: association between an oncogenic receptor tyrosine kinase and drug-induced DNA repair. Cancer Res. 1994; 54(14):3758-65. View

DiGiovanna M, Carter D, Flynn S, Stern D . Functional assay for HER-2/neu demonstrates active signalling in a minority of HER-2/neu-overexpressing invasive human breast tumours. Br J Cancer. 1996; 74(5):802-6. PMC: 2074709. DOI: 10.1038/bjc.1996.439. View

Klapper L, Glathe S, Vaisman N, Hynes N, ANDREWS G, Sela M . The ErbB-2/HER2 oncoprotein of human carcinomas may function solely as a shared coreceptor for multiple stroma-derived growth factors. Proc Natl Acad Sci U S A. 1999; 96(9):4995-5000. PMC: 21805. DOI: 10.1073/pnas.96.9.4995. View

10.

Kato S, Endoh H, Masuhiro Y, Kitamoto T, Uchiyama S, Sasaki H . Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase. Science. 1995; 270(5241):1491-4. DOI: 10.1126/science.270.5241.1491. View

11.

Gassmann M, Casagranda F, Orioli D, Simon H, Lai C, Klein R . Aberrant neural and cardiac development in mice lacking the ErbB4 neuregulin receptor. Nature. 1995; 378(6555):390-4. DOI: 10.1038/378390a0. View

12.

Kim H, Sierke S, Koland J . Epidermal growth factor-dependent association of phosphatidylinositol 3-kinase with the erbB3 gene product. J Biol Chem. 1994; 269(40):24747-55. View

13.

Moscatello D, Godwin A, Ramirez G, Gunn G, Zoltick P, Biegel J . Frequent expression of a mutant epidermal growth factor receptor in multiple human tumors. Cancer Res. 1995; 55(23):5536-9. View

14.

Burke C, Stern D . Activation of Neu (ErbB-2) mediated by disulfide bond-induced dimerization reveals a receptor tyrosine kinase dimer interface. Mol Cell Biol. 1998; 18(9):5371-9. PMC: 109122. DOI: 10.1128/MCB.18.9.5371. View

15.

Prenzel N, Zwick E, Leserer M, Ullrich A . Tyrosine kinase signalling in breast cancer. Epidermal growth factor receptor: convergence point for signal integration and diversification. Breast Cancer Res. 2001; 2(3):184-90. PMC: 138773. DOI: 10.1186/bcr52. View

16.

Di Fiore P, PIERCE J, Kraus M, Segatto O, King C, Aaronson S . erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells. Science. 1987; 237(4811):178-82. DOI: 10.1126/science.2885917. View

17.

Antoniotti S, Maggiora P, Dati C, De Bortoli M . Tamoxifen up-regulates c-erbB-2 expression in oestrogen-responsive breast cancer cells in vitro. Eur J Cancer. 1992; 28(2-3):318-21. DOI: 10.1016/s0959-8049(05)80045-0. View

18.

Di Fiore P, PIERCE J, Fleming T, Hazan R, Ullrich A, King C . Overexpression of the human EGF receptor confers an EGF-dependent transformed phenotype to NIH 3T3 cells. Cell. 1987; 51(6):1063-70. DOI: 10.1016/0092-8674(87)90592-7. View

19.

Slamon D, Clark G, Wong S, Levin W, Ullrich A, McGuire W . Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987; 235(4785):177-82. DOI: 10.1126/science.3798106. View

20.

Kenney N, Huang R, Johnson G, Wu J, Okamura D, Matheny W . Detection and location of amphiregulin and Cripto-1 expression in the developing postnatal mouse mammary gland. Mol Reprod Dev. 1995; 41(3):277-86. DOI: 10.1002/mrd.1080410302. View